

Supplementary Table 1 Baseline characteristics for 451 patients with multiple sclerosis treated with rituximab at 22 Italian and 1 Swiss centers, by MS subtype

Characteristics	All patients N=451	Relapsing Remitting N=246	Primary Progressive N=52	Secondary Progressive N=153
Age at MS onset, years, mean (sd)	30.4 (11.3)	28.7 (10.6)	41.4 (11.5)	29.3 (10.2)
Gender (Female), n (%)	301 (66.7)	175 (71.1)	30 (57.7)	96 (62.8)
MS duration, years, mean (sd)	12.8 (9.0)	10.8 (8.2)	7.0 (5.8)	18.0 (8.7)
Comorbidity, n (%)	184 (40.9)	94 (38.4)	20 (38.5)	70 (45.7)
Autoimmune comorbidity, n (%)	62 (13.8)	47 (19.3)	2 (3.9)	13 (8.6)
EDSS 6 months pre RTX, median (range)	4.5 (0-8.5)	3 (0-8.5)	5.5 (1.5-7.5)	6.0 (1.5-8.5)
EDSS at RTX start, median (range)	4.5 (0-8.5)	3 (0-8.5)	5.5 (1.5-7.5)	6.0 (2.0-8.5)
No. Relapse 2 yrs pre-RTX, median (range)	1 (0-10)	1 (0-10)	0 (0-3)	0 (0-4)
No. Relapse 1 yr pre-RTX, median (range)	1 (0-7)	1 (0-7)	0 (0-2)	0 (0-5)
Presence of Active MRI 1 yr pre-RTX, n (%)	213/365 (58.4)	135/193 (70.0)	20/39 (51.3)	58/133 (43.6)
Presence of Spinal Lesions at baseline, n (%)	154/323 (47.7)	96/165 (58.2)	14/32 (43.7)	44/126 (34.9)
Naïve patients, n (%)	48 (10.6)	26 (10.6)	17 (32.7)	5 (3.3)
Previous treatments, median (range)	2 (0-7)	2 (0-7)	1 (0-5)	3 (0-7)
First Line Previous treatment, median (range)	1 (0-6)	1 (0-6)	0 (0-3)	2 (0-6)
Second Line Previous treatment, median (range)	1 (0-4)	1 (0-3)	0 (0-2)	1 (0-4)
Last DMT before RTX, n (%)	N=403	N=220	N=35	N=148
Alemtuzumab	5 (1.2)	3 (1.4)	0 (0.0)	2 (1.3)
Cyclophosphamide	21 (5.2)	8 (3.7)	6 (17.1)	7 (4.7)
Daclizumab	1 (0.2)	1 (0.5)	0 (0.0)	0 (0.0)
Dimethyl fumarate	43 (10.7)	28 (12.8)	3 (8.6)	12 (8.1)
Fingolimod	97 (24.1)	49 (22.4)	10 (28.6)	38 (25.7)
Glatiramer acetate	39 (9.7)	21 (9.6)	1 (2.9)	17 (11.5)
Interferons	52 (12.9)	24 (11.0)	4 (11.4)	24 (16.2)

Characteristics	All patients N=451	Relapsing Remitting N=246	Primary Progressive N=52	Secondary Progressive N=153
Natalizumab	82 (20.4)	62 (28.3)	3 (8.6)	17 (11.5)
HSCT	3 (0.7)	2 (0.9)	0 (0.0)	1 (0.7)
Teriflunomide	21 (5.2)	11 (5.0)	1 (2.9)	9 (6.1)
Other	38 (9.4)	10 (4.6)	7 (20.0)	21 (14.2)
Reasons for changing to RTX, n (%)	N=403	N=220	N=35	N=148
Poor efficacy	232 (57.6)	112 (50.9)	21 (60.0)	99 (66.9)
Intolerance/Adverse event	68 (16.9)	37 (16.8)	10 (28.6)	21 (14.2)
JCV+	39 (9.7)	28 (12.7)	1 (2.9)	10 (6.8)
Pregnancy	9 (2.2)	8 (3.6)	1 (2.9)	0 (0.0)
Other	55 (13.6)	35 (15.9)	2 (5.7)	18 (12.2)
Induction regimen, n (%)				
two 375 mg/m ² infusions 15 days apart	25 (5.5)	17 (6.9)	2 (3.9)	6 (3.9)
two 1000 mg infusions 15 days apart	392 (86.9)	201 (81.7)	48 (92.3)	143 (93.5)
four 375 mg/m ² infusions every week for 4 weeks	27 (6.0)	24 (9.8)	0 (0.0)	3 (2.0)
1000 every 6 months (no induction)	7 (1.6)	4 (1.6)	2 (3.9)	1 (0.7)

sd: standard deviation; EDSS: Expanded Disability Status Scale; DMT: disease-modifying treatment; HSCT: hematopoietic stem cell transplantation; JCV+: Positive for John Cunningham virus